Mark Ragosa is CHIEF FINANCIAL OFFICER of Kiniksa Pharmaceuticals, Ltd.. Currently has a direct ownership of 22,958 shares of KNSA, which is worth approximately $500,484. The most recent transaction as insider was on Sep 02, 2024, when has been sold 956 shares (Class A Ordinary Share) at a price of $26.74 per share, resulting in proceeds of $25,563. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 23K
19.24% 3M change
46.87% 12M change
Total Value Held $500,484

Mark Ragosa Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 02 2024
SELL
Payment of exercise price or tax liability
$25,563 $26.74 p/Share
956 Reduced 4.0%
22,958 Class A Ordinary Share
Sep 02 2024
BUY
Exercise of conversion of derivative security
-
1,861 Added 7.22%
23,914 Class A Ordinary Share
Sep 01 2024
SELL
Payment of exercise price or tax liability
$60,432 $26.74 p/Share
2,260 Reduced 9.3%
22,053 Class A Ordinary Share
Sep 01 2024
BUY
Exercise of conversion of derivative security
-
4,444 Added 15.45%
24,313 Class A Ordinary Share
Jul 23 2024
SELL
Open market or private sale
$601,107 $24.79 p/Share
24,248 Reduced 55.74%
19,253 Class A Ordinary Share
Jul 23 2024
BUY
Exercise of conversion of derivative security
$269,152 $11.1 p/Share
24,248 Added 35.79%
43,501 Class A Ordinary Share
Apr 26 2024
SELL
Payment of exercise price or tax liability
$9,100 $17.88 p/Share
509 Reduced 2.58%
19,253 Class A Common Share
Apr 26 2024
BUY
Exercise of conversion of derivative security
-
991 Added 4.78%
19,762 Class A Common Share
Apr 08 2024
SELL
Payment of exercise price or tax liability
$14,158 $17.9 p/Share
791 Reduced 4.04%
18,771 Class A Common Share
Apr 08 2024
BUY
Exercise of conversion of derivative security
-
2,694 Added 12.1%
19,562 Class A Common Share
Apr 01 2024
SELL
Payment of exercise price or tax liability
$10,125 $19.7 p/Share
514 Reduced 2.96%
16,868 Class A Common Share
Apr 01 2024
BUY
Exercise of conversion of derivative security
-
1,750 Added 9.15%
17,382 Class A Common Share
Jan 03 2024
SELL
Open market or private sale
$240,000 $20.0 p/Share
12,000 Reduced 43.43%
15,632 Class A Common Share
Jan 03 2024
BUY
Exercise of conversion of derivative security
$105,960 $8.83 p/Share
12,000 Added 30.28%
27,632 Class A Common Share
Sep 02 2023
SELL
Payment of exercise price or tax liability
$9,714 $17.76 p/Share
547 Reduced 3.38%
15,632 Class A Common Share
Sep 02 2023
BUY
Exercise of conversion of derivative security
-
1,861 Added 10.32%
16,179 Class A Common Share
Sep 01 2023
SELL
Payment of exercise price or tax liability
$14,048 $17.76 p/Share
791 Reduced 5.24%
14,318 Class A Common Share
Sep 01 2023
BUY
Exercise of conversion of derivative security
-
2,695 Added 15.14%
15,109 Class A Common Share
Apr 26 2023
SELL
Payment of exercise price or tax liability
$3,244 $11.15 p/Share
291 Reduced 2.29%
12,414 Class A Common Share
Apr 26 2023
BUY
Exercise of conversion of derivative security
-
990 Added 7.23%
12,705 Class A Common Share
Apr 10 2023
SELL
Payment of exercise price or tax liability
$8,471 $10.71 p/Share
791 Reduced 6.32%
11,715 Class A Common Share
Apr 10 2023
BUY
Exercise of conversion of derivative security
-
2,695 Added 17.73%
12,506 Class A Common Share
Mar 20 2023
SELL
Payment of exercise price or tax liability
$7,050 $11.12 p/Share
634 Reduced 6.07%
9,811 Class A Common Share
Mar 20 2023
BUY
Exercise of conversion of derivative security
-
2,158 Added 17.12%
10,445 Class A Common Share
Mar 16 2023
SELL
Payment of exercise price or tax liability
$2,933 $11.46 p/Share
256 Reduced 3.0%
8,287 Class A Common Share
MR

Mark Ragosa

CHIEF FINANCIAL OFFICER
Hamilton, D0

Track Institutional and Insider Activities on KNSA

Follow Kiniksa Pharmaceuticals, Ltd. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA